Cost-effectiveness of the treatment with salmeterol-fluticasone in comparison with Montelukast leukotriene for the control of childhood asthma;Costo-Efectividad del Tratamiento de Salmeterol/Fluticasona en Comparación con Leucotrieno Montelukast para el Control del Asma Infantil

Value in Health

Volumn 14, Issue 5 SUPPL., 2011, Pages

  Rely, Kely ^a   McQuire, Sebastián Emanuel González ^b   Alexandre, Pierre K ^c   Escudero, Guillermo Salinas ^d  

^a CEAHealthTech   (Mexico)

^b Glaxo Smith Kline   (Mexico)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; MONTELUKAST;

ADOLESCENT; ARTICLE; ASTHMA; CHILD; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEXICO; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; ECONOMIC ASPECT; HEALTH CARE; OPEN STUDY; OUTCOME ASSESSMENT; PROBABILITY; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ACETATES; ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; DRUG COSTS; HOSPITALIZATION; HUMANS; MEXICO; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; QUINOLINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052629805     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.05.033     Document Type: Article

References (30)

1. S.S. Braman The global burden of asthma Chest 130 Suppl. 2006 4S 12S (Pubitemid 44107231)
2. Estudio Europeo del Asma Prevalencia de hiperreactividad bronquial y asma en adultos jóvenes de cinco áreas espaolas Grupo Espaol del Estudio Europeo del Asma Med Clin (Barc.) 106 1996 761 767
3. O.I. Aguinaga, P.A. Arnedo, J. Bellido, and G.F. Guillen Prevalencia de síntomas relacionados con el asma en nios de 1314 aos de 9 poblaciones espaolas Grupo Espaol del Estudio ISAAC Med Clin (Barc.) 112 1999 171 175
4. M. Callén, E. Alstiza, and C. Solórzano Prevalencia de asma y factores de riesgo de asma en Guipzcoa: estudio multicéntrico caso-control An Esp Pediatr 43 1995 347 350
5. Grupo Espaol para el Manejo del Asma Guía espaola para el manejo del asma Arch Bronconeumol 39 Suppl. 5 2003 1 42
6. F.G. Rico, S. Barquera, D.A. Cabrera, and S. Escobedo Bronquial asthma healthcare costs in Mexico: analysis of trends from 1991-1996 with information from the Mexican Institute of Social Security Invest Allergol Clin Immunol 10 2000 334 341 (Pubitemid 32113027)
7. Pan American Health Organization Health in the Americas 2002 PAHO Washington, DC
8. Global Initiative for Asthma Global strategy for asthma management and prevention http://www.ginasthma.com/ [Acceso julio 2004]
9. Scottish Intercollegiate Guidelines Group A guideline developers' handbook Publication No. 50 2001 SIGN Edinburgh
10. British Guideline on the Management of Asthma A national clinical guideline Revisted edition April 2004 BGMA Edinburgh
11. Guía de Práctica Clínica de Asma Comarca Gipuzkoa Este Servicio Vasco de Salud 1999 Osakidetza País Vasco
12. J. Maspero, F. Guerra, F. Cuevas, and J.P. Gutierrez Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective randomized, double-blind, double-lummy, paralel group study Clin Ther 30 2008 1492 1504
13. 2-agonist alone Am J Respir Crit Care Med 164 2001 759 763 (Pubitemid 32881910)
14. I. Pavord, A. Woodcook, D. Parker, and L. Rice Salmeterol plus flucasone propionate versus fluticasone propionate plus montelukast: a randomized controlled trial investigating the effects on among inflammation in asthma Respir Res 8 2007 67
15. C. Powell The Delphi technique: myths and realities J Adv Nurs 41 2003 376 382 (Pubitemid 37255969)
16. H.P. McKenna The Delphi technique: a worthwile approach for nursing? J Adv Nurs 19 1994 1221 1225
17. Instituto Nacional de Salud Pública de México Propuesta de guías para la conducción de estudios de evaluación económica como parte de la actualización de los cuadros básico de insumos para la salud del Consejo de Salubridad General 2007 Consejo de Salubridad General [Informe] Ciudad de México D. F
18. Secretaría General del IMSS Costos unitarios para la determinación de créditos fiscales derivados de capitales constitutivos, inscripciones improcedentes y atención a no derechohabientes 2009 Diario Oficial de la Federación [Informe] Ciudad de México D. F
19. Global Initiative for Asthma Global strategy for asthma management and prevention Rev. NIH publication; no. 02-3659 2002 National Institutes of Health, National Heart, Lung, and Blood Institute Bethesda, Md
20. F. Antoanzas Evaluación económica aplicada a los medicamentos: características y metodología J. Sacristán, X. Badía, J. Rovira, Farmacoeconomía: evaluación económica de los medicamentos 1995 Editores Médicos Madrid
21. A.H. Briggs, R. Goeree, G. Blackhouse, and B. O'Brien Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease Med Decis Making 22 2002 290 308 (Pubitemid 34791317)
22. A.H. Briggs Handling uncertainty in cost-effectiveness models Pharmacoeconomics 17 2000 479 500 (Pubitemid 30398806)
23. K. Claxton, M. Schupher, and C. McCabe Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra Health Econ 14 2005 339 347 (Pubitemid 40514748)
24. N.J. Van den Berg, M.S. Ossip, and C.A. Hederos Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma Pediatr Pulmonol 30 2000 97 105
25. M.J. Price, and A.H. Briggs Development of an economic model to assess the cost effectiveness of asthma management strategies Pharmacoeconomics 20 2002 183 194 (Pubitemid 34454643)
26. P.J. Barnes Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids Eur Respir J 19 2002 182 191 (Pubitemid 34105586)
27. K.A. Lyseng-Williamson, and G.L. Plosker Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma PharmacoEconomics 21 2003 951 989 (Pubitemid 37222569)
28. K. Sheth, R. Borker, and A. Emmett Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma Pharmacoeconomics 20 2002 909 918 (Pubitemid 35252841)
29. R.D. O'Connor, H. Nelson, and R. Borker Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Pharmacoeconomics 22 2004 815 825 (Pubitemid 39158999)
30. W.R. Pieters, K.K. Wilson, and H.C. Smith Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma Treat Respir Med 4 2005 129 138 (Pubitemid 40613961)